ATE409065T1 - Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten - Google Patents
Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheitenInfo
- Publication number
- ATE409065T1 ATE409065T1 AT03790505T AT03790505T ATE409065T1 AT E409065 T1 ATE409065 T1 AT E409065T1 AT 03790505 T AT03790505 T AT 03790505T AT 03790505 T AT03790505 T AT 03790505T AT E409065 T1 ATE409065 T1 AT E409065T1
- Authority
- AT
- Austria
- Prior art keywords
- hydroxysteroid dehydrogenase
- inhibitors
- treatment
- compounds
- androgen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43410102P | 2002-12-17 | 2002-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE409065T1 true ATE409065T1 (de) | 2008-10-15 |
Family
ID=32713010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03790505T ATE409065T1 (de) | 2002-12-17 | 2003-12-15 | Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
Country Status (12)
Country | Link |
---|---|
US (3) | US7053091B2 (de) |
EP (1) | EP1572299B1 (de) |
JP (1) | JP4585320B2 (de) |
CN (1) | CN1744930A (de) |
AT (1) | ATE409065T1 (de) |
AU (1) | AU2003293555A1 (de) |
CA (1) | CA2509758A1 (de) |
DE (1) | DE60323765D1 (de) |
ES (1) | ES2312845T3 (de) |
HK (1) | HK1074592A1 (de) |
MX (1) | MXPA05006485A (de) |
WO (1) | WO2004060488A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60323765D1 (de) * | 2002-12-17 | 2008-11-06 | Schering Corp | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
KR101235090B1 (ko) * | 2004-04-13 | 2013-02-20 | 인사이트 코포레이션 | 케모킨 수용체 길항제로서의 피페라지닐피페리딘 유도체 |
US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
KR100869540B1 (ko) * | 2004-08-06 | 2008-11-19 | 샤프 가부시키가이샤 | 송신기, 수신기, 통신시스템, 통신방법, 통신프로그램을 기록한 컴퓨터 독취가능한 기록매체 |
AU2006230187B2 (en) | 2005-03-29 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Methods for generating new hair follicles, treating baldness, and hair removal |
GB0513702D0 (en) * | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
WO2007130712A1 (en) * | 2006-01-31 | 2007-11-15 | Janssen Pharmaceutica, Nv | Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
ES2775000T3 (es) | 2009-04-02 | 2020-07-23 | Merck Patent Gmbh | Derivados de piperidina y piperazina como inhibidores de autotaxina |
JP2014500275A (ja) | 2010-12-06 | 2014-01-09 | フォリカ,インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
WO2014207311A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1 |
WO2014207309A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 b-hydroxysteroid dehydrogenase, type 1 |
SG11201510251TA (en) | 2013-06-25 | 2016-01-28 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
DE102014005129A1 (de) | 2014-04-08 | 2014-11-06 | Daimler Ag | Verfahren und Fahrerassistenzvorrichtung zur Unterstützung eines Fahrers beim Führen eines Fahrzeugs |
JP6523461B2 (ja) | 2014-12-23 | 2019-06-05 | フォレンド ファーマ リミテッド | 17β−HSD1−阻害剤のプロドラッグ |
JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | 17β‐HSD1抑制剤のプロドラッグ |
CN105461705B (zh) * | 2015-11-30 | 2018-04-10 | 中国医科大学 | 二苯并氮杂卓二酮类抗肿瘤化合物及其制备方法 |
CN115716860A (zh) | 2017-06-08 | 2023-02-28 | 佛恩多制药有限公司 | 15β-[3-丙酰氨基]-取代的雌-1,3,5(10)-三烯-17-酮及17-肟 |
KR20210114390A (ko) | 2018-12-05 | 2021-09-23 | 포렌도 파마 리미티드 | 17-hsd1의 억제제로서의 피라졸 고리와 위치 16(17)에서 축합된 에스트라-1,3,5(10)-트리엔 화합물 |
CN112321515A (zh) * | 2020-10-21 | 2021-02-05 | 上海馨远医药科技有限公司 | 一种手性1-叔丁基-3-甲基-6-甲基哌嗪-1,3-二甲酸酯的制备方法 |
CN112321538A (zh) * | 2020-10-28 | 2021-02-05 | 都创(上海)医药开发有限公司 | 一种合成单胺保护的哌嗪-(r/s)2-甲酸酯的方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU594309B2 (en) | 1984-08-02 | 1990-03-08 | Fernand Labrie | Pharmaceutical composition for combination therapy of hormonedependent cancers |
ES2077675T3 (es) | 1989-03-10 | 1995-12-01 | Endorecherche Inc | Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos. |
KR920703063A (ko) | 1989-07-07 | 1992-12-17 | 원본미기재 | 양성 전립선 비대증의 예방 및/ 또는 치료를 위한 복합요법 |
CA2062792C (en) | 1989-07-07 | 2006-03-21 | Fernard Labrie | Treatment of androgen-related diseases |
US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
WO1994026767A1 (en) | 1993-05-17 | 1994-11-24 | Endorecherche Inc. | Improved antiandrogens |
US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
CA2323089A1 (en) | 1998-03-11 | 1999-09-16 | Endorecherche, Inc. | Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use |
US6673799B1 (en) * | 1998-09-22 | 2004-01-06 | Yamanouchi Pharmaceutical Co. Ltd. | Cyanophenyl derivative |
US6362188B1 (en) * | 1998-12-18 | 2002-03-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
ID29065A (id) * | 1998-12-18 | 2001-07-26 | Schering Corp | Penghambat-penghambat farnesil protein transferase |
PT1423381E (pt) * | 2001-09-06 | 2007-04-30 | Schering Corp | Inibidores de 17-b-hidroxiesteróide-desidrogenase do tipo 3 para o tratamento de doenças dependentes de androgénio |
EP1436281B1 (de) * | 2001-10-17 | 2010-06-16 | Schering Corporation | Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
DE60332862D1 (de) | 2002-11-18 | 2010-07-15 | Schering Corp | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen |
DE60323765D1 (de) * | 2002-12-17 | 2008-11-06 | Schering Corp | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
-
2003
- 2003-12-15 DE DE60323765T patent/DE60323765D1/de not_active Expired - Lifetime
- 2003-12-15 WO PCT/US2003/039863 patent/WO2004060488A1/en active Application Filing
- 2003-12-15 US US10/735,983 patent/US7053091B2/en not_active Expired - Fee Related
- 2003-12-15 EP EP03790505A patent/EP1572299B1/de not_active Expired - Lifetime
- 2003-12-15 ES ES03790505T patent/ES2312845T3/es not_active Expired - Lifetime
- 2003-12-15 JP JP2004565490A patent/JP4585320B2/ja not_active Expired - Fee Related
- 2003-12-15 AT AT03790505T patent/ATE409065T1/de not_active IP Right Cessation
- 2003-12-15 CN CNA2003801094364A patent/CN1744930A/zh active Pending
- 2003-12-15 CA CA002509758A patent/CA2509758A1/en not_active Abandoned
- 2003-12-15 MX MXPA05006485A patent/MXPA05006485A/es active IP Right Grant
- 2003-12-15 AU AU2003293555A patent/AU2003293555A1/en not_active Abandoned
-
2005
- 2005-09-22 HK HK05108331A patent/HK1074592A1/xx not_active IP Right Cessation
-
2006
- 2006-02-23 US US11/360,711 patent/US7271175B2/en not_active Expired - Fee Related
-
2007
- 2007-08-09 US US11/836,530 patent/US7485645B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20080004248A1 (en) | 2008-01-03 |
CA2509758A1 (en) | 2004-07-22 |
JP2006514054A (ja) | 2006-04-27 |
US7271175B2 (en) | 2007-09-18 |
WO2004060488A1 (en) | 2004-07-22 |
AU2003293555A1 (en) | 2004-07-29 |
DE60323765D1 (de) | 2008-11-06 |
JP4585320B2 (ja) | 2010-11-24 |
MXPA05006485A (es) | 2005-08-26 |
US20060142338A1 (en) | 2006-06-29 |
ES2312845T3 (es) | 2009-03-01 |
EP1572299A1 (de) | 2005-09-14 |
US7053091B2 (en) | 2006-05-30 |
US20040138226A1 (en) | 2004-07-15 |
US7485645B2 (en) | 2009-02-03 |
CN1744930A (zh) | 2006-03-08 |
HK1074592A1 (en) | 2005-11-18 |
EP1572299B1 (de) | 2008-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE409065T1 (de) | Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
PT1347971E (pt) | Inibidores tiazolilicos de tirosina-cinases da familia tec | |
HUP0102160A2 (hu) | Alfa-keto-enamin-származékok alkalmazása alkotórészként | |
HRP20050262A2 (en) | Pyrrolidone derivatives as maob inhibitors | |
EA200501805A1 (ru) | Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы | |
NO20060978L (no) | Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering | |
WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
SE0001899D0 (sv) | New compounds | |
MXPA05005223A (es) | Diaminotriazoles utiles como inhibidores de proteinas cinasas. | |
MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
TW200514772A (en) | Novel tetrahydropyridine derivatives | |
MY130792A (en) | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | |
ATE273690T1 (de) | Zusammensetzung zur hautdesinfizierung | |
NO20055612L (no) | Anti-inflammatoriske fosfonatforbindelser | |
MXPA04002009A (es) | Composicion farmaceutica que comprende gabapentina o un analogo de la misma y alfa-aminoamida y su uso como analgesico. | |
DE602004017871D1 (de) | Zubereitungen zur behandlung von arthritischen erscheinungen | |
RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
WO2004052236A3 (en) | Methods and compositions for treatment of otitis media | |
MXPA05013226A (es) | Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas. | |
RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |